MNMD (Mind Medicine) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mind Medicine's Free Cash Flow for the three months ended in Dec. 2024 was $-25.35 Mil. Mind Medicine's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Mind Medicine's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Mind Medicine's current FCF Yield % is -16.96%.

The historical rank and industry rank for Mind Medicine's FCF Margin % or its related term are showing as below:

MNMD's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.165
* Ranked among companies with meaningful FCF Margin % only.

Mind Medicine FCF Margin % Historical Data

The historical data trend for Mind Medicine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine FCF Margin % Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Mind Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Mind Medicine's FCF Margin %

For the Biotechnology subindustry, Mind Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mind Medicine's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Mind Medicine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mind Medicine's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-79.129	/	0
	=	%

Mind Medicine's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-25.351	/	0
	=	%

Mind Medicine FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mind Medicine's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MMQ:Germany

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Executives

Mark Sullivan	officer: Chief Legal Officer	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Robert Barrow	director, officer: Chief Executive Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin	officer: Chief Medical Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao	officer: VP, Controller&Acct Principal	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Schond L. Greenway	officer: Chief Financial Officer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Carol A Vallone	director	490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs	director	5 GIRALDA FARMS, MADISON NJ 07940
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal	director	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu	officer: Chief Legal Officer&Secretary	6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli	director, officer: Executive President	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007